Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shih-Chia Hsiao"'
Autor:
Zih-Fei Cheng, Hao-Kang Li, Hsiu-Ping Yang, Chia-Yun Lee, Sai-Wen Tang, Yan-Liang Lin, Shih-Chia Hsiao
Publikováno v:
Biochemistry and Biophysics Reports, Vol 26, Iss , Pp 100935- (2021)
Natural killer (NK) cells, as a potential source for off-the-shelf cell therapy, attack tumor cells with low risk of severe cytokine release syndrome (CRS) or graft-versus-host disease (GvHD). Fcγ receptor IIIA, also known as CD16, further confers N
Externí odkaz:
https://doaj.org/article/dd71282f93ff47fe816406326f50a763
Autor:
Hao-Kang Li, Tai-Sheng Wu, Yi-Chiu Kuo, Ching-Wen Hsiao, Hsiu-Ping Yang, Chia-Yun Lee, Pei-Ju Leng, Zih-Fei Cheng, Sen-Han Yang, Yang-Liang Lin, Shih-Chia Hsiao, Sai-Wen Tang
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Hao-Kang Li, Tai-Sheng Wu, Pei-Ru Leng, Yi-Chiu Kuo, Zih-Fei Cheng, Chia-Yun Lee, Yan-Liang Lin, Sai-Wen Tang, Shih-Chia Hsiao
Publikováno v:
Cancer Research. 83:LB089-LB089
Introduction: CAR-αβT therapies have been shown to improve clinical outcomes in hematological malignancies; however, solid tumors still remain as challenges to CAR-αβT therapies due to tumor microenvironment, limited tumor infiltration or antigen
Autor:
Hao-Kang Li, Chia-Yun Lee, Sai-Wen Tang, Hsiu-Ping Yang, Yan-Da Lai, Janet Pan, Tai-Sheng Wu, Shih-Chia Hsiao, Sen-Han Yang, Yan-Liang Lin, Ching-Wen Hsiao, Zih-Fei Cheng
Publikováno v:
Cancers, Vol 13, Iss 2724, p 2724 (2021)
Cancers
Volume 13
Issue 11
Cancers
Volume 13
Issue 11
Simple Summary Chimeric antigen receptor T cell therapy has shown its potency against hematologic malignancies in autologous settings but also limited success against solid tumors with severe adverse events, including fatal cases of cytokine releasin
Autor:
Ching-Wen Hsiao, Zih-Fei Cheng, Chia-Yun Lee, Tai-Sheng Wu, Shih-Chia Hsiao, Hao-Kang Li, Janet Pan, Wei-Lun Lo, Yan-Liang Lin, Yan-Da Lai, Sen-Han Yang, Sai-Wen Tang, Hsiu-Ping Yang
Publikováno v:
Late-breaking abstracts.
Background Autologous or allogeneic natural killer (NK) cells possess efficient cytotoxicity against tumor cells without severe side effects such as CRS or graft-versus-host disease (GvHD). In addition to chimeric antigen receptor (CAR) strategy, ant
Autor:
Chia-Yun Lee, Sai-Wen Tang, Zih-Fei Cheng, Hsiu-Ping Yang, Yan-Liang Lin, Shih-Chia Hsiao, Hao-Kang Li
Publikováno v:
Biochemistry and Biophysics Reports
Biochemistry and Biophysics Reports, Vol 26, Iss, Pp 100935-(2021)
Biochemistry and Biophysics Reports, Vol 26, Iss, Pp 100935-(2021)
Natural killer (NK) cells, as a potential source for off-the-shelf cell therapy, attack tumor cells with low risk of severe cytokine release syndrome (CRS) or graft-versus-host disease (GvHD). Fcγ receptor IIIA, also known as CD16, further confers N
Autor:
Jiun-Jie Shie, An-Suei Yang, Shi-Yun Wang, Jim-Min Fang, Shih-Chia Hsiao, Ching-Yao Su, Chi-Huey Wong, Keng-Chang Tsai, Yih-Shyun E. Cheng
Publikováno v:
Journal of the American Chemical Society. 129(39)
Using d-xylose as an appropriate chiral precursor, we have synthesized active neuraminidase inhibitor oseltamivir, antiflu drug Tamiflu, and novel phosphonate congeners that exhibit even stronger antiflu activities by inhibiting the neuraminidases of